D-0306-2020 Class III Terminated
FDA drug recall D-0306-2020 was initiated by Lupin Pharmaceuticals Inc. on Nov 1, 2019 and is designated Class III. Reason for recall: Presence of Foreign substance: identified as a dead ant. The recall status is terminated (terminated Mar 4, 2021). Affected quantity: a) 4074 bottles b) 30,300 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 13, 2019
- Initiation Date
- Nov 1, 2019
- Termination Date
- Mar 4, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 4074 bottles b) 30,300 bottles
Product description
Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA
Reason for recall
Presence of Foreign substance: identified as a dead ant.
Distribution pattern
Product was distributed to major distributors/wholesalers throughout the United States.
Code information
Lot #: a) F900153, Exp 11/20; b) F802327, F802328, F802329, Exp 11/20
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0306-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026